Department of Urology, Urology Institute of PLA, Southwest Hospital, Third Military Medical University (Army Medical University), Gao Tanyan Street 29#, Sha Pingba, Chongqing, 400038, China.
BMC Urol. 2020 Mar 30;20(1):36. doi: 10.1186/s12894-020-00597-3.
To evaluate the efficacy of submucosal injection of triamcinolone acetonide for the treatment of type II/III interstitial cystitis/bladder pain syndrome.
A retrospective analysis of the clinical data of type II/III interstitial cystitis/bladder pain syndrome patients treated in our department from April 2016 to August 2018 was conducted, and changes in International Prostate Symptom Scores and the Pelvic Pain and Urgency/Frequency symptom scale after surgery were evaluated to explore factors that may affect patient outcomes.
A total of 27 female patients and 8 male patients were enrolled, with type II patients accounting for 62.9% of the sample, and the median follow-up duration was 31 months (range: 12-40 months). Twenty-two patients (74.3%) had significantly improved questionnaire scores at 4 weeks postoperatively. Treatment efficacy was sustained for at least 1 year in 15 patients, and persistent effectiveness was noted in 10 (28.6%) patients. Patients with an advanced age (p = 0.015), high pain scores (p = 0.040), and higher International Prostate Symptom Scores (p = 0.037) and Pelvic Pain and Urgency/Frequency symptom scale scores (p = 0.020) were more likely to benefit from submucosal injection of triamcinolone acetonide. Gender, disease duration, and the presence of Hunner's lesions had no predictive value for treatment outcomes.
Submucosal injection of triamcinolone acetonide can improve the clinical symptoms and quality of life in both men and women with type II/III interstitial cystitis/bladder pain syndrome. Patients with an advanced age and more severe interstitial cystitis/bladder pain syndrome related symptoms may benefit more from triamcinolone acetonide injection.
评估曲安奈德混悬液黏膜下注射治疗 II/III 型间质性膀胱炎/膀胱疼痛综合征的疗效。
回顾性分析 2016 年 4 月至 2018 年 8 月我科收治的 II/III 型间质性膀胱炎/膀胱疼痛综合征患者的临床资料，评估术后国际前列腺症状评分和盆腔疼痛及急迫/频度症状评分的变化，探讨可能影响患者预后的因素。
共纳入 27 例女性和 8 例男性患者，II 型患者占样本的 62.9%，中位随访时间为 31 个月（12-40 个月）。22 例（74.3%）患者术后 4 周时问卷评分明显改善。15 例患者治疗效果至少持续 1 年，10 例（28.6%）患者持续有效。年龄较大（p=0.015）、疼痛评分较高（p=0.040）、国际前列腺症状评分和盆腔疼痛及急迫/频度症状评分较高（p=0.037、0.020）的患者更可能从曲安奈德混悬液黏膜下注射中获益。性别、疾病持续时间和 Hunner 病变的存在对治疗结果没有预测价值。
曲安奈德混悬液黏膜下注射可改善 II/III 型间质性膀胱炎/膀胱疼痛综合征男性和女性患者的临床症状和生活质量。年龄较大和间质性膀胱炎/膀胱疼痛综合征相关症状更严重的患者可能从曲安奈德注射中获益更多。
